Table IV:

Multivariable Regressions Predicting Awareness of, Current Use of, and Intention to Use PrEP Among Mexican GSN App Users in 2018–2019

Variable	Awareness of PrEP n=2,020		Current Use of PrEP n=1,642 a		Intention to Use PrEP n=1,584 a
	aOR [95% CI]	p value	aOR [95% CI]	p value	aOR [95% CI]	p value
PrEP Eligible b,d
Yes c	1.86 [1.19–2.91]	0.006	26.07 [13.05–52.09]	< 0.001	1.37 [0.98–1.91]	0.062
Recent (12 months) STI Testing e
Yes c	1.79 [1.39–2.30]	< 0.001	3.79 [1.10–13.11]	0.035	1.05 [0.82–1.34]	0.714
Recent (3 months) Chemsex f,g
Yes c	0.75 [0.40–1.42]	0.381	3.02 [1.02–8.93]	0.046	1.71 [0.94–3.10]	0.078

Bolded aORs had a p value of ≤ 0.05

^aCurrent use of PrEP includes only those who had heard of PrEP (n=1,642); intention to use PrEP includes only those who had heard of PrEP who were not currently taking PrEP (n=1,584)

^bRecent PEP use and STI diagnosis, both of which are PrEP eligibility criteria in the PAHO guidelines (29), were used to create the PrEP eligible variable

^cCompared against “No”

^dRegression models for PrEP eligible included the following confounders: age, city population size, recent STI testing, chemsex, and doctor as source of PrEP information

^eRegression models for recent STI testing included the following confounders: age, city population size, HIV status, PrEP eligible, chemsex, and doctor as source of PrEP information

^fRegression models for recent chemsex included the following confounders: age, city population size, PrEP eligible, recent STI testing, and friends as source of PrEP information

^gSurvey question specified the following drugs: Mephedrone, GHB/GBL, Ketamine, Methamphetamine. GHB and GBL stand for gamma hydroxybutyrate and gamma butyrolactone, respectively. However only the abbreviation was used in the survey

Abbreviations: aOR (adjusted odds ratio), CI (confidence interval), PrEP (pre-exposure prophylaxis), STI (sexually transmitted infection)